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Efforts to target glutamine metabolism for cancer
therapy have focused on the glutaminase isozyme
GLS. The importance of the other isozyme, GLS2, in
cancer has remained unclear, and it has been
described as a tumor suppressor in some contexts.
Here, we report that GLS2 is upregulated and essen-
tial in luminal-subtype breast tumors, which account
for >70% of breast cancer incidence. We show that
GLS2 expression is elevated by GATA3 in luminal-
subtype cells but suppressed by promoter methyl-
ation in basal-subtype cells. Although luminal breast
cancers resist GLS-selective inhibitors, we find that
they can be targeted with a dual-GLS/GLS2 inhibitor.
These results establish a critical role for GLS2 inmam-
mary tumorigenesis and advance our understanding
of how to target glutamine metabolism in cancer.SIGNIFICANCE
Humans have two genes encoding glutaminase enzymes, GLS
andGLS2. Efforts to target glutamine catabolism for cancer ther-
apy have focused on GLS, an inhibitor of which (CB-839) is
currently in clinical trials. The GLS2 isozyme has previously
been described as a tumor suppressor, with downregulated
expression in liver cancer. We report here that GLS2 is overex-
pressed and essential for growth in the most prevalent subtypes
of breast cancer, luminal A andB. AlthoughGLS2 is insensitive to
CB-839-class drugs, it is inhibited by the small molecule 968,
which suppresses breast tumor growth in vivo. These findings
establish a critical role for GLS2 in breast cancer and advance
our understanding of how to target aberrant glutamine meta-
bolism for cancer therapy.76 Cell Reports 29, 76–88, October 1, 2019 ª 2019 The Authors.
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Sustained biomass accumulation in tumors depends on cancer
cells acquiring nutrients from the environment and processing
them tomeet the biosynthetic, bioenergetic, and redox demands
of proliferation (Pavlova and Thompson, 2016). Many oncogenic
signaling pathways regulate the expression, activity, or localiza-
tion of nutrient transporters and metabolic enzymes, and
extrinsic factors such as O2 availability also influence cellular
metabolism (Vander Heiden and DeBerardinis, 2017). These var-
iables cause cancer cell metabolism to be highly heterogeneous
in nature, although certain metabolic alterations are consistently
observed in diverse tumor types. For example, most tumors
exhibit elevated glucose uptake coupled to lactate secretion
regardless of O2 availability (the Warburg effect), and cancer
cells also frequently depend on an exogenous supply of gluta-
mine (Pavlova and Thompson, 2016).
Glutamine is the most abundant amino acid in blood serum and
is amajor source of carbon and nitrogen for tumor cells. Its uptake
into cells is facilitated by plasmamembrane transporters, which in
some cases are essential for tumorigenesis (van Geldermalsen
et al., 2016). Once in the cytosol, there are several possible fates
for glutamine in addition to its role as a proteinogenic amino acid.
In mitochondria, glutamine catabolism is initiated by glutaminase,
which releases the amide nitrogen as ammonia to generate gluta-
mate. In turn, glutamate can be incorporated into the glutathione
and proline biosynthesis pathways, or deaminated to produce the
tricarboxylic acid (TCA) cycle intermediate a-ketoglutarate (a-KG).
Thismetabolic pathway is widely upregulated in cancer cells, with
glutamine serving as a key anaplerotic substrate for the TCA cycle
(Cluntun et al., 2017).
Two genes encode glutaminases inmammals,GLS andGLS2,
and different isoforms of each enzyme arise from alternative
splicing and surrogate promoter mechanisms (Katt et al.,
2017). TheGLS isozyme is ubiquitous in healthy tissues, whereas
liver-type glutaminase (GLS2) is restricted primarily to the liver,creativecommons.org/licenses/by-nc-nd/4.0/).
pancreas, and brain (Altman et al., 2016). Expression of GLS is
regulated by oncogenic transcription factors, and its role in can-
cer is well characterized and supportive of tumorigenesis (Gao
et al., 2009; Lukey et al., 2016). Consequently, GLS has been
investigated as a possible drug target for cancer therapy, and
an allosteric inhibitor, CB-839, is currently being evaluated in
clinical trials (Gross et al., 2014). The function of GLS2 in cancer
is less well defined and appears to be context dependent. The
GLS2 gene is a transcriptional target of p53 (Hu et al., 2010;
Suzuki et al., 2010), and in glioblastoma and liver cancer GLS2
has been described as a tumor suppressor (Mate´s et al.,
2018). However, GLS2 expression is also regulated by oncopro-
teins including N-myc (Xiao et al., 2015) and was identified as
one of only 16 essential metabolic genes for tumorigenesis in a
functional genomics screen (Possemato et al., 2011).
Here, we describe a critical onco-supportive role for GLS2 in
breast cancer. We demonstrate that expression of the GLS2
gene is regulated by GATA3 and that the gene product is essen-
tial for cell proliferation and tumorigenesis in luminal-subtype
breast cancers, which account for 75% of total breast cancer
incidence (Table S1) (Dai et al., 2015). Moreover, we show that
GLS2 can be targeted with the small-molecule inhibitor 968 to
suppress tumorigenesis and overcome resistance to GLS-selec-
tive inhibitors. These findings establish a previously unappreci-
ated essential role for GLS2 in breast cancer biology and
provide important insights regarding how to target glutamine
metabolism for cancer therapy.
RESULTS
Luminal Breast Cancers Use Glutamine Anaplerosis but
Resist GLS Inhibitors
The most extensively studied inhibitors of GLS are based on
the bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl) ethyl sulfide
(BPTES) molecular scaffold, with the potent analog CB-839
currently in clinical trials for a number of malignancies. CB-839
was originally reported to be effective against triple-negative
breast cancer (TNBC) cells (Gross et al., 2014), which are charac-
terized by low expression of the receptors estrogen receptor (ER),
progesterone receptor (PR), and HER2. Across a collection of
breast cancer cell lines, we observed that basal-subtype cells
respond to BPTES or CB-839 treatment, whereas luminal-sub-
type cells resist these inhibitors, regardless of their specific recep-
tor status (Figure 1A; Tables S2 and S3). We previously reported
the same selectivity profile for the related inhibitor UPGL00004,
indicating that this entire class of molecules is ineffective against
luminal-subtype breast cancers (Huang et al., 2018).
However, the sensitivity of breast cancer cells to GLS inhibitors
does not correspond to their rate of glutamine consumption or to
their expression of SLC1A5 (Figures 1B and 1C), the major facili-
tator of glutamine uptake in breast cancer (van Geldermalsen
et al., 2016). We therefore used stable isotope tracing to deter-
mine the fate of glutamine-derived carbon in the different breast
cancer subtypes (Figure S1A). Cells were cultured inmediumcon-
taining uniformly labeled 13C-glutamine for 10 h, and metabolites
were then extracted for analysis by liquid chromatography-high-
resolution mass spectrometry (LC-HRMS). In both basal-subtype
(MDA-MB-231 and TSE) and luminal-subtype (T-47D andMDA-MB-453) cells, glutamine is a major source of carbon for
the TCA cycle (Figure 1D). The proportion of the TCA cycle inter-
mediates a-KG and fumarate derived directly from [U-13C]-gluta-
mine (i.e., the abundance ratio of m+5 a-KG and m+4 fumarate)
ranges from30% to55%. The abundance ratio of m+4 citrate
ranges from 18% to 35%, whereas only trace quantities of m+5
citrate are present in all cell lines, indicating that the TCA cycle
is turning in the oxidative direction under the aerobic experimental
conditions. The abundance of TCA cycle metabolites showed no
consistent differences between luminal- and basal-subtype cells
(Figure S1B), and samples collected at different time points (1 h,
24 h) had similar labeling patterns to those collected at 10 h (Fig-
ure S1C). Thus, both luminal- and basal-subtype breast cancer
cells make use of glutamine as an anaplerotic substrate, despite
their contrasting sensitivity to GLS inhibitors.
Expression of GLS2 Is Elevated in Luminal-Subtype
Breast Cancers
Previously, the glutaminase isozyme GLS2 has been described
as a tumor suppressor in some contexts, with downregulated
expression in liver and brain cancers (Mate´s et al., 2018).
However, since luminal-subtype breast cancer cells resist GLS
inhibitors yet still exhibit glutamine-mediated anaplerosis, we hy-
pothesized that they might instead be dependent on GLS2. We
used The Cancer Genome Atlas (TCGA) invasive breast cancer
dataset (Koboldt et al., 2012) to examine GLS2 transcript levels
in the breast cancer molecular subtypes luminal A (LumA),
luminal B (LumB), HER2+, and basal. Expression of GLS2 is
indeed substantially higher in LumA and LumB tumors than in
basal-subtype tumors, which instead have high levels of the
GLS transcript (Figure 2A).
To compare protein levels of GLS2 in breast tumors and
normal mammary tissue, we probed a tissue microarray (Figures
2B, 2C, and S2A). This revealed that GLS2 levels are significantly
upregulated in receptor-positive breast tumors (the majority of
which are luminal subtype) relative to normal tissue but are
elevated only in a small number of receptor-negative breast tu-
mors (generally basal subtype), with the mean level not differing
significantly from normal tissue (Figure 2B). Microscopic exami-
nation of the stained tissue slices revealed that in receptor-pos-
itive tumors, GLS2 is much more abundant in carcinoma cells
than in neighboring connective tissue (Figure 2C). We then
confirmed that the expression patterns for GLS and GLS2 are
conserved in breast cancer cell lines. Quantitative real-time
PCR analysis showed that the GLS2 transcript is up to 2,000-
fold more abundant in luminal-subtype than in basal-subtype
cells, which predominantly express GLS (Figures 2D and 2E).
These differences are conserved at the protein level (Figure 2F).
Consistent with other reports (Muir et al., 2017; Shin et al., 2017),
high levels of GLS in basal-subtype cells are associated with
expression of the glutamate/cystine antiport system ‘‘xCT’’ and
corresponding rapid glutamate efflux (Figures S2B and S2C).
GLS2 Is Localized to Mitochondria in Breast Cancer
Cells
Although GLS2 contains a predicted mitochondrial localization
signal (Katt et al., 2017), several subcellular localizations have
been reported, including the nucleus in neurons and astrocytesCell Reports 29, 76–88, October 1, 2019 77
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Figure 1. Luminal-Subtype Breast Cancer Cells Use Glutamine to Supply the TCA Cycle, but Resist GLS Inhibitors
(A) The effect of the GLS inhibitors BPTES and CB-839 on proliferation of basal-subtype (MDA-MB-231 and TSE) and luminal-subtype (MDA-MB-453 and T-47D)
breast cancer cells over 6 days. Mean ± SD of triplicate assays.
(B) Glutamine consumption rates, per milligram of total cellular protein, of breast cancer cell lines. Mean ± SD of biological triplicates.
(C) Western blot showing relative levels of SLC1A5 in breast cancer cell lines. Note that SLC1A5 is an integral membrane protein subject to covalent post-
translational modifications including glycosylations, which cause it to run at a range of molecular weights on SDS-PAGE.
(D) Abundance ratios of fully labeled intracellular glutamine, glutamate, and TCA cycle metabolites in breast cancer cells supplied with [U-13C]-glutamine for 10 h.
Mean ± SEM of biological triplicate samples.
See also Figure S1 and Tables S1–S3.and as a binding partner of the plasmamembrane/cytosolic pro-
tein Rac1 in liver cancer cells (Cardona et al., 2015; Zhang et al.,
2016). To establish the localization of GLS2 in breast cancer
cells, we fractionated both MDA-MB-453 (high-GLS2) and
MDA-MB-231 cells (high-GLS) and performed western blot anal-
ysis on the whole-cell lysates along with the cytosolic, mitochon-
drial, and nuclear fractions. As markers for these fractions, we
also probed for the cytosolic enzyme asparagine synthetase
(ASNS), the mitochondrial voltage-dependent anion channel
(VDAC), and the nuclear envelope protein lamin A. Both GLS2
and GLS, along with VDAC, were detected almost exclusively
in the mitochondrial fractions of both cell lines (Figure 2G). A
small proportion of each glutaminase was present in the nuclear
fractions, but the similar pattern for VDAC suggests that these
signals arise from small quantities of mitochondria co-pelleting78 Cell Reports 29, 76–88, October 1, 2019with nuclei (Figure 2G). As expected, ASNS was detected in
the cytosolic fraction, and lamin A in the nuclear fraction (Fig-
ure 2G). We also examined the subcellular localization of ectop-
ically expressed GLS2 using immunofluorescence. Supporting a
mitochondrial localization for GLS2 in breast cancer cells, GLS2-
HA co-localizes with the endogenous mitochondrial marker pro-
tein Hsp60 in SK-BR-3 cells, as well as with ectopically ex-
pressed GLS-myc (Figure S2D).
GLS2 Expression Is Regulated by GATA3 and Promoter
Methylation
To understand the upregulation of GLS2 in luminal-subtype
breast cancers, we next investigated the mechanisms influ-
encing GLS2 gene expression. Data from TCGA show a high
frequency of copy number gains at the GLS2 gene locus in
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Figure 2. GLS2 Is Upregulated in Luminal-Subtype Breast Cancers
(A) Box and whisker plots showing transcript levels ofGLS2 (left panel) andGLS (right panel) in the molecular subtypes of breast cancer. RNA-seq V2 RSEM data
are from The Cancer Genome Atlas invasive breast cancer dataset. Themean expression in each group is indicated by a cross, and the box andwhiskers indicate
the minimum, first quartile, median, third quartile, and maximum values. **p% 0.01.
(B) Relative GLS2 protein levels in tissue microarray slices of normal mammary tissue, receptor-positive, and receptor-negative breast tumors.
**p % 0.01.
(C) Microscopy images of breast tissuemicroarray slices stained brown for GLS2. Representative images are shown for normal breast tissue alongwith receptor-
positive and receptor-negative breast tumors. Scale bars, 200 mm.
(legend continued on next page)
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luminal-subtype and HER2+ breast tumors (as high as 37% copy
number gain, 2% gene amplification, in the case of LumB), but
not in basal-subtype tumors (Figure S3A). The GLS locus ex-
hibits the reverse pattern, with frequent copy number gains in
basal-subtype and HER2+ breast tumors, but not in LumA or
LumB (Figure S3A). The transcription factors p53, p63, p73,
c-Myc, and N-myc have each been shown to regulate GLS2
expression in different contexts (Katt et al., 2017). However,
we found that none of these regulators correlates with the
pattern of GLS2 expression in breast cancer cells (Figure 3A),
and we note that the TP53 gene encoding p53 is mutated in
BT-474, T-47D, MDA-MB-231, Hs 578T, and HCC38 cells. We
therefore investigated whether additional factors contribute to
the regulation of GLS2 expression in breast cancer.
Across the cell lines, there is no clear association between
GLS2 levels and any one of the receptors ER, PR, or HER2,
with MDA-MB-453 cells, which have low expression of all three
receptors, having the highest GLS2 levels (Figure 3B). Since
GLS2 is so abundant in LumA and LumB breast cancers relative
to other subtypes, we wondered whether its expression is intrin-
sically associated with luminal cell status. Levels of GLS2 in
breast cancer cell lines correlate closely with that of full-length
GATA3 (Figure 3B), a ‘‘master regulator’’ of luminal differentiation
(Asselin-Labat et al., 2007). There is also a strong positive corre-
lation between GATA3 and GLS2 transcript levels in human
breast tumors (Figure 3C). We therefore used PROMO (Farre´
et al., 2003; Messeguer et al., 2002) to analyze the human
GLS2 gene promoter, and identified a match to the GATA3
consensus motif at position 1,259 base pairs (bp) relative to
the transcription start site (TSS) (Figure S3B). The probability of
this sequence occurring randomly within 1,500 bp of the TSS
is predicted by PROMO to be only 2.8%. We next carried out a
chromatin immunoprecipitation (ChIP), pulling down GATA3
from cross-linked chromatin prepared from MDA-MB-453 cell
nuclei and using quantitative real-time PCR to quantify a 176-
bp stretch of the GLS2 promoter centered on the GATA3
consensus motif. The GATA3 pull-down yielded a6-fold higher
signal relative to input than a negative-control IgG IP, consistent
with direct binding of GATA3 to this region of the promoter (Fig-
ure 3D). Finally, we knocked down GATA3 in MDA-MB-453 and
T-47D cells and found that, after 48 h, this resulted in a corre-
sponding decrease in GLS2 levels in each cell line (Figures 3E
and S3D). Thus, GATA3 contributes to the elevated expression
of GLS2 in luminal-subtype breast cancers.
Because GLS2 levels are so low in basal-subtype breast can-
cers, we also tested whether expression is epigenetically
silenced in these cells via methylation of the GLS2 gene pro-
moter. After isolating genomic DNA from the basal-subtype(D) Quantitative real-time PCR data showing relative levels of GLS2 transcript in b
indicate the RQmax and RQmin values.
(E) Quantitative real-time PCR data showing relative levels of GLS transcript in b
indicate the RQmax and RQmin values.
(F)Western blots showing relative levels of GLS andGLS2 in breast cancer cell line
and Hs 578T lysates, is labeled N/S.
(G)Western blots of whole-cell lysates (WCLs), and cytosolic, mitochondrial, and n
Lamin A serve as mitochondrial, cytosolic, and nuclear marker proteins, respect
See also Figure S2.
80 Cell Reports 29, 76–88, October 1, 2019cell lines with the lowest levels of GLS2 transcript (TSE and Hs
578T) and the luminal-subtype cell lines with the highest levels
(T-47D and MDA-MB-453), we used the MassARRAY system
to quantify methylation levels at sites in the CpG island centered
on the TSS of the GLS2 gene (Figures S3B and S3C). In MDA-
MB-453 cells, which have the highest levels of GLS2, there is
minimal promoter methylation, whereas in TSE cells, which
have the lowest levels of GLS2 transcript, almost every site
within the CpG island has a high methylation ratio (Figure 3F).
Treatment of TSE cells with the DNA hypomethylating agent aza-
citidine for 48 h resulted in increased GLS2 protein levels (Fig-
ure 3G). Collectively, these results show that GLS2 expression
is regulated by GATA3 in luminal-subtype breast cancers, and
potentially also by copy number gains, whereas expression in
basal-subtype breast cancers is repressed by promoter
methylation.
GLS2 Mediates Glutamine Anaplerosis in Luminal-
Subtype Cells
To probe the role of GLS2 in luminal-subtype cells, we asked
whether GLS2 is involved in the observed supply of glutamine-
derived carbon to the TCA cycle (Figure 1D). For comparison,
we also quantified the anaplerotic role of GLS in basal-subtype
breast cancer cells. We transduced MDA-MB-453 (luminal,
high-GLS2) or MDA-MB-231 (basal, high-GLS) cells with con-
structs for expressing a control short hairpin RNA (shRNA) or
shRNAs targeting GLS2 or GLS. After 48 h, we confirmed knock-
downs using western blot analysis, and observed that within this
time frame there was no compensatory upregulation of the other
glutaminase isozyme (Figure 4A). We then performed metabolo-
mics experiments to assess the effects of the knockdowns on
TCA cycle anaplerosis. Importantly, knockdown of GLS2
strongly inhibited glutamine-mediated TCA cycle anaplerosis in
MDA-MB-453 cells (Figure 4B). As expected, knockdown of
GLS in MDA-MB-231 cells also suppressed the delivery of car-
bon from [U-13C]-glutamine into the TCA cycle (Figure 4B). The
glutaminase knockdowns also decreased the total abundance
of glutamate and TCA cycle intermediates (Figure S4A). As a
control, we carried out the reciprocal experiment, treating
MDA-MB-453 cells with GLS-targeted shRNAs, and MDA-MB-
231 cells with GLS2-targeted shRNAs. In each case, the abun-
dance of glutamate and TCA cycle metabolites was minimally
perturbed (Figure S4B), further demonstrating that GLS2 is the
predominant glutaminase in MDA-MB-453 cells and that GLS
is the primary isozyme in MDA-MB-231 cells. Collectively, these
findings establish that GLS2 is a metabolically active mitochon-
drial enzyme, critical for glutamine-mediated anaplerosis in
luminal-subtype breast cancer cells.reast cancer cell lines. Reactions were carried out in triplicate, and error bars
reast cancer cell lines. Reactions were carried out in triplicate, and error bars
s. A non-specific band from theGLS2 antibody, clearly visible forMDA-MB-231
uclear fractions fromMDA-MB-453 andMDA-MB-231 cells. VDAC, ASNS, and
ively.
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Figure 3. GLS2 Gene Expression Is Regulated by GATA3 and Promoter Methylation
(A) Western blots showing relative levels of GLS2, and previously identified transcription factors for the GLS2 gene, in breast cancer cell lines.
(B) Western blots showing relative levels of GLS2, the luminal-transcription factor GATA3, and the receptors ERa, PR, and HER2 in breast cancer cell lines.
(C) Plot of GLS2 and GATA3 transcript levels in human breast tumors, with the Pearson correlation coefficient r indicated. RNA-seq V2 RSEM data from TCGA
invasive breast cancer dataset.
(D) Quantitative real-time PCR data showing relative levels of a 176-bp fragment of the GLS2 gene promoter, centered on the putative GATA3 binding site, in
chromatin immunoprecipitations (ChIPs) using negative control IgG or a GATA3-targeted antibody. Mean ± SD of biological triplicate samples.
(E) Western blots showing GLS2 and GATA3 levels in MDA-MB-453 and T-47D cells transfected with either a control siRNA (labeled C) or with two independent
GATA3-targeted siRNAs. Bands in the GLS2 blot were quantified by densitometry using ImageJ, and relative band intensities are indicated above the blot. Since
GATA3 regulates expression of Tubulin and several other cytoskeletal proteins, a non-specific (N/S) band is shown to demonstrate equal loading.
(F) Heatmaps showing relative methylation levels at CpG sites within the CpG island of the GLS2 gene promoter in breast cancer cell lines. Labels for the CpG
sites refer to the amplicon in which the sites are located (amplicons 0 to 9) and then the position of the site within that amplicon (i.e., first CpG site, second CpG
(legend continued on next page)
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GLS2 Is Essential in Luminal-Subtype Breast Cancer
Cells
Because various functions have been reported for GLS2 in can-
cer, including tumor-suppressive activity in liver cancer and glio-
blastoma (Mate´s et al., 2018), we next investigated the impor-
tance of GLS2 for breast cancer cell proliferation and
tumorigenesis. We transfected luminal- and basal-subtype cell
lines with either a control small interfering RNA (siRNA) or
siRNAs selectively targeting GLS2, GLS, or both isozymes simul-
taneously. Western blot analysis 48 h after transfection
confirmed that potent and selective knockdowns had been
achieved (Figure 4C, lower panels). We then measured cell pro-
liferation over 6 days. Knockdown of GLS2 strongly suppressed
proliferation of luminal-subtype cells (MDA-MB-453 and T-47D),
but only modestly impacted proliferation of basal-subtype cells
(MDA-MB-231 and TSE) (Figure 4C, upper panels). Knockdown
of GLS had no effect on luminal-subtype cells but did inhibit
basal-subtype cells, consistent with the results usingGLS-selec-
tive inhibitors (Figure 1A). In all cases, the effects of GLS2 and/or
GLS knockdowns could be rescued by supplementation of the
culture medium with 2 mM dimethyl a-KG (dm-a-KG) (Fig-
ure S4C), confirming that suppressed proliferation was a result
of impaired TCA cycle anaplerosis.
We next addressed the importance of GLS2 for luminal-sub-
type breast tumor growth in vivo. This experiment required stable
rather than transient depletion of GLS2, but potent shRNA-medi-
ated knockdowns severely impacted luminal-subtype cell
viability after several days. We therefore used a low titer of virus
for transducing MDA-MB-453 cells and generated stable GLS2
partial-knockdown cell lines (Figure 4D). Proliferation of the
GLS2 partial-knockdown cells in culture was 40%–50% slower
than that of cells expressing a control shRNA (Figure 4E, left
panel), and could be rescued with 2 mM dm-a-KG (Figure 4E,
right panel). We then injected 3 3 106 control or GLS2 partial-
knockdown cells, in Matrigel suspension, into each flank of
female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice, and
measured tumor growth over 42 days (n = 6 tumors per condi-
tion). Both tumor initiation time and the rate of tumor growth
were strongly inhibited in the GLS2 partial-knockdown samples
relative to the control, providing a proof of principle that targeting
GLS2 can inhibit luminal-subtype breast cancer tumorigenesis
in vivo as well as cell proliferation ex vivo (Figure 4F).
GLS2 Mediates Resistance to GLS Inhibitors
The BPTES class of inhibitors has been extensively studied and
is highly selective for GLS over GLS2 (Figures S5A and S5B)
(Robinson et al., 2007). Since GLS2 is capable of mediating
TCA cycle anaplerosis in breast cancer cells, we tested whether
it is sufficient to confer resistance to these inhibitors. We began
by looking at the inhibition of glutaminase activity in isolated
mitochondria. In mitochondria from luminal-subtype breast can-
cer cells, glutaminase activity was only partially inhibited bysite, etc.). Numbers missing in the sequence are for sites at which methylation rati
only a single reading is shown for sites covered by more than one amplicon.
(G) Western blot showing relative levels of GLS2 in TSE cells treated with different
the GLS2 blot were quantified by densitometry using ImageJ, and relative band
See also Figure S3.
82 Cell Reports 29, 76–88, October 1, 2019addition of 10 mM BPTES (Figure 5A). In the case of MDA-MB-
453 cells, BPTES treatment had no effect on activity. As ex-
pected, for mitochondria isolated from basal-subtype cells,
glutaminase activity was almost completely abolished by
10 mM BPTES (Figure 5A).
To gain further insight into the glutaminase expression profiles
of breast cancer cells, we performedwestern blot analyses using
known amounts of purified, recombinant GLS and GLS2 to esti-
mate absolute levels of each glutaminase in cells (Figure S5C).
We found that MDA-MB-453 cells contain 275 pg of GLS2
per mg of total cellular protein and 75 pg/mg GLS. In contrast,
MDA-MB-231 cells contain 500 pg/mg GLS and <75 pg/mg
GLS2 (Figure S5C). In T-47D cells, the absolute levels of GLS
and GLS2 are approximately equal, at 200 pg/mg (Figure S5C).
However, GLS requires much higher concentrations of inorganic
phosphate (Pi) to reach maximal activity (Figure 5B), and in
contrast to GLS2, its enzymatic activity is inhibited by its prod-
uct, glutamate (Watford, 1993). At physiological mitochondrial
Pi concentrations of 10 mM (Hutson et al., 1992; Rauch
et al., 1994), only GLS2 is fully activated (Figure 5B).
We next treated cells with 10 mM BPTES in culture medium
containing [U-13C]-glutamine and extracted and analyzed
cellular metabolites. Consistent with the data above, BPTES
treatment potently inhibited the supply of glutamine-derived
carbon to glutamate and the TCA cycle in the basal-subtype
cell lines Hs 578T and MDA-MB-231 (Figure 5C). In luminal-
subtype MCF7 cells, which express GLS2 as well as GLS,
BPTES treatment partially blocked glutamine anaplerosis
(Figure 5C). In MDA-MB-453 cells, which express primarily
GLS2, BPTES treatment had no impact on glutamine-medi-
ated anaplerosis (Figure 5C). A similar pattern can be seen
in the total abundances of TCA cycle intermediates
(Figure S5D).
Using MDA-MB-231 and TSE cells, which express almost
exclusively GLS, we generated derivative cell lines that ectopi-
cally express GLS2 (Figure 5D). In both cases, the clone with
highest GLS2 expression showed a moderate decrease in the
level of GLS. Although forced overexpression of GLS2 hinders
the growth of liver cancer cells (Hu et al., 2010; Suzuki et al.,
2010), in basal-subtype breast cancer cells each of the GLS2-
overexpressing clones proliferated slightly more rapidly than
control cells (Figure S5E). Ectopic expression of GLS2 greatly
decreased sensitivity to BPTES treatment, with the EC50 shifting
to >20 mM for both cell lines, which matches the aqueous solubi-
lity limit of the inhibitor (Figure 5E; Table S4).
We then searched for basal-subtype breast cancer cells that
are intrinsically resistant to GLS-selective inhibitors, to test
whether resistance can be overcome by simultaneously target-
ing GLS2. The triple-negative, basal-subtype breast cancer cell
line DU4475, which was originally derived from a metastatic
lesion, is highly resistant to BPTES treatment, with an EC50 value
of >20 mM (Figure 5F). Western blot analysis showed thatos could not be determined. Although the amplicons were designed to overlap,
concentrations of the DNA hypomethylating agent azacitidine for 48 h. Bands in
intensities are indicated above the blot. A non-specific band is labeled N/S.
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Figure 4. GLS2 Is Essential in Luminal-Subtype Breast Cancers
(A) Western blots showing GLS and GLS2 levels in MDA-MB-453 cells and MDA-MB-231 cells expressing either a control shRNA or two independent GLS2-
targeted (MDA-MB-453 cells) or GLS-targeted (MDA-MB-231 cells) shRNAs.
(B) Fold changes in fully labeled glutamate and TCA cycle metabolites (i.e., derived directly from [U-13C]-glutamine) inMDA-MB-453 cells following knockdown of
GLS2, or in MDA-MB-231 cells following knockdown of GLS. Mean ± SEM of biological triplicates.
(C) The effect of knocking down either GLS, GLS2, or both GLS and GLS2 simultaneously, on the proliferation of breast cancer cell lines over 6 days. For each
condition, two independent siRNAs were used, and the effects were compared with those of a control siRNA (labeled C). Mean ± SD of triplicate assays. Lower
panels show western blots for GLS and GLS2 in each sample. *p% 0.05; **p% 0.01; ns, not significant.
(D) Western blot showing partial knockdown of GLS2 in MDA-MB-453 stably expressing two independent GLS2-targeted shRNAs, relative to cells stably
expressing a control shRNA.
(legend continued on next page)
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DU4475 cells express higher levels of GLS than MDA-MB-231
cells, but simultaneously express higher levels of GLS2 than
MDA-MB-453 cells (750 pg/mg of cellular protein for GLS,
and 625 pg/mg for GLS2) (Figures 5G and S5C). Knockdown
of either glutaminase isozyme alone did not impact DU4475
cell proliferation, but simultaneous knockdown of both GLS
and GLS2 significantly inhibited growth (Figures 5H and S5F).
Proliferation was again restored by supplementation of the cul-
ture medium with 2 mM dm-a-KG (Figure S5G).
968 Inhibits GLS2 and Suppresses BPTES-Resistant
Breast Cancer Growth
Previously, we reported that the small molecule 968 binds and
inhibits the GLS splice variant GAC (Wang et al., 2010). This in-
hibitor has a much higher affinity for monomeric GAC than for
the active tetramer and is proposed to bind to newly synthesized
enzyme monomers and prevent the formation of activated tetra-
mers (Stalnecker et al., 2015). However, the sensitivity of GLS2
to 968 has not previously been tested. We therefore measured
the effect of 968 on the activity of purified, recombinant, gluta-
minase. In contrast to BPTES-class inhibitors, which are highly
selective for GLS, 968 inhibited both GLS andGLS2, with amod-
erate (>3-fold) selectivity for GLS2 (Figure 6A). Compound 26, a
quinoline derivative of 968 that differs by only a single carbon-to-
nitrogen substitution, has greatly weakened affinity for GLS (Katt
et al., 2012; Stalnecker et al., 2015). Similarly, we found that
compound 26 minimally inhibits recombinant GLS2 at 50 mM,
whereas 968 completely blocks activity at this concentration
(Figure S6A).
Treatment of breast cancer cells with 968 inhibited prolifera-
tion with EC50 values of 3–5 mM (Figure S6B; Table S4). For the
cells with highest expression of GLS, maximal inhibition was
70%–75%. The inactive analog compound 26 did not inhibit
the proliferation of any of the cell lines we tested it against.
Despite their intrinsic resistance to BPTES, DU4475 cells re-
sponded to 968 treatment with an EC50 value of 4 mM (Figure 6B).
We also measured the response of the GLS2-overexpressing
derivatives of MDA-MB-231 and TSE cells, described above.
Consistent with the ability of 968 to inhibit both glutaminase iso-
zymes, overexpression of GLS2 had little effect on the EC50
values for 968 (Table S4).
We next treated basal- and luminal-subtype breast cancer
cells with 10 mM 968 and extracted metabolites for analysis at
different time points. Consistent with the mechanism of 968
binding to monomeric glutaminase and preventing the formation
of active tetramers, we observed a time-dependent inhibition of
glutamine-mediated TCA cycle anaplerosis (Figure 6C). Match-
ing the partial selectivity of 968 for GLS2 over GLS, the effects
were more pronounced in MDA-MB-453 cells than MDA-MB-
231 cells (Figure 6C). Treatment with 968 also decreased the to-
tal abundance of TCA cycle intermediates (Figure S6C).(E) Inhibition of proliferation over 6 days for MDA-MB-453 cells stably expressin
(labeled C). Experiments were run either without (left panel) or with (right panel)
(dm-a-KG). Mean ± SD of triplicate assays. *p% 0.05; **p% 0.01; ns, not signifi
(F) Growth of xenograft tumors in mice by MDA-MB-453 cells stably expressing e
(n = 6 tumors per condition). *p% 0.05; **p% 0.01.
See also Figure S4.
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ex vivo but does not affect the growth of primary human mam-
mary epithelial cells or fibroblasts (Wang et al., 2010), we tested
whether it can be used to treat luminal-subtype breast tumor
growth in vivo. We injected 3 3 106 MDA-MB-453 cells in
Matrigel suspension into each flank of NSG mice (n = 6 xeno-
grafts per condition) and waited until palpable tumors 1–2 mm
in diameter were present (14 days). At this point, mice were
separated into two groups, with one group receiving subcutane-
ous injections of 968 (10 mg/kg body weight) 3 times per week,
and the other group receiving carrier solution only. We continued
tomonitor tumor growth for 3weeks after initiating treatment and
found that it was robustly inhibited in 968-treated animals (Fig-
ure 6D). In contrast, treatment of animals with 10 mg/kg BPTES
did not significantly impact tumor growth (Figure 6E). Thus, 968
inhibits GLS2 in vitro, suppresses GLS2-mediated anaplerosis,
and is effective against BPTES-resistant breast cancer cell pro-
liferation and tumorigenesis. Taken together, our results reveal
an essential and potentially druggable role for GLS2 in luminal-
subtype breast cancers.
DISCUSSION
Efforts to target glutamine catabolism for cancer therapy have
focusedon inhibiting theglutaminase isozymeGLS,which ishighly
expressed and onco-supportive in diverse malignancies (Cluntun
et al., 2017). The importance of the othermammalian glutaminase,
GLS2, in tumorigenesis has remained less clear, and various sub-
cellular localizations and functions havebeendescribed, including
tumor suppressor activity (Mate´s et al., 2018). We report here that
GLS2 is upregulated in luminal-subtype/receptor-positive breast
cancers, where it is essential for glutamine-mediated TCA cycle
anaplerosis, cell proliferation, and tumorigenesis. These findings
explain the identification of GLS2 as one of only 16 metabolic en-
zymes required for tumorigenesis in an earlier functional genomics
screen (Possemato et al., 2011).
Previous studies found that triple-negative, but not receptor-
positive, breast cancer cell lines often express high levels of
the GLS splice variant GAC (Gross et al., 2014). Our results indi-
cate that, rather than being directly dictated by the cellular re-
ceptor status, differences in glutaminase expression in breast
cancer correspond to the intrinsic molecular subtype (Figure 2).
Specifically, LumA and LumB breast tumors display relatively
high levels of GLS2, whereas GLS is elevated in basal-subtype
breast tumors. Since expression of the GLS2 gene is driven in
part by the transcription factor GATA3 (Figure 3), a master regu-
lator of luminal differentiation, high levels of GLS2might be intrin-
sically associated with luminal cell status. Expression of both
glutaminase isozymes is low in HER2+ breast tumors, suggesting
that glutaminase-mediated TCA cycle anaplerosis might not be a
major metabolic pathway in this disease subtype.g GLS2-targeted shRNAs, relative to cells stably expressing a control shRNA
supplementation of the culture medium with 2 mM dimethyl a-ketoglutarate
cant.
ither a control shRNA or two independent GLS2-targeted shRNAs. Mean ± SD
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Figure 5. GLS2 Expression Is Sufficient for Resistance to GLS Inhibitors
(A) Inhibition of glutaminase activity by 10 mM BPTES in mitochondria isolated from breast cancer cell lines. Plot shows activity in the presence of 10 mM BPTES
relative to matched samples with no BPTES present. Mean ± SD of triplicate assays.
(B) The effect of increasing inorganic phosphate concentrations on the catalytic activity of recombinant full-length human GLS (GAC splice variant) and GLS2.
Mean ± SD of triplicate assays.
(C) Fold changes in fully labeled intracellular metabolites (i.e., derived directly from [U-13C]-glutamine) in basal-subtype (top) and luminal-subtype (bottom) breast
cancer cell lines, following treatment with 10 mM BPTES. Mean ± SEM of triplicates relative to the vehicle.
(D) Western blots showing levels of endogenous GLS and ectopically expressed V5-tagged GLS2 in MDA-MB-231 and TSE cells.
(E) Inhibition of proliferation over 6 days of MDA-MB-231 and TSE cells, stably expressing GLS2 (two clones for each cell line) or carrying the plasmid vector only,
by treatment with different concentrations of BPTES. Mean ± SD of triplicate assays.
(F) The effect of different concentrations of BPTES on proliferation of DU4475 cells over 6 days. Mean ± SD of triplicate assays.
(G) Western blots showing relative levels of GLS and GLS2 in MDA-MB-453, MDA-MB-231, and DU4475 cells. A non-specific band from the GLS antibody is
marked N/S.
(H) The effect of knocking down either GLS or GLS2, or both GLS and GLS2 simultaneously, on the proliferation of DU4475 cells over 6 days. For each condition,
two independent siRNAs were used, and the effects were compared with those of a control siRNA (labeled C). Mean ± SD of triplicate assays. **p% 0.01; ns, not
significant.
See also Figure S5 and Table S4.
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Figure 6. 968 Inhibits GLS2 and Suppresses BPTES-Resistant
Breast Cancer Growth
(A) Inhibition of purified recombinant full-length human GLS (GAC splice
variant) or GLS2 by different concentrations of 968. Mean ± SD of triplicate
assays.
(B) The effect of different concentrations of 968 or BPTES on proliferation of
DU4475 cells over 6 days. Mean ± SD of triplicate assays.
(C) Fold changes in fully labeled intracellular metabolites, derived directly from
[U-13C]-glutamine, when breast cancer cells are treated with 10 mM968 for the
indicated periods of time. Mean ± SEM of triplicates relative to the vehicle.
(D) Growth of MDA-MB-453 xenograft tumors in mice. Once palpable tumors
were detected (at day 14), mice were divided into two groups, one of which
received subcutaneous injections of 10 mg/kg 968 three times per week,
while the other received carrier solution only. Mean ± SD (n = 6 tumors per
condition). **p% 0.01.
(E) Plot showing the final size of MDA-MB-453 xenograft tumors following
treatment ofmice with 10mg/kg 968, 10mg/kg BPTES, or carrier solution only,
three times per week from day 14 until day 35. Mice were sacrificed at day 35,
and tumors were excised prior to measurement. Mean ± SD (n = 6 tumors per
condition). **p% 0.01; ns, not significant.
See also Figure S6 and Table S4.Our findings highlight the importance of considering GLS2
when identifying target diseases for treatment with GLS-selective
inhibitors. Gene expression data fromTCGAshow thatGLS2 tran-
script levels are consistently upregulated relative to healthy tissue86 Cell Reports 29, 76–88, October 1, 2019in colorectal tumors and also in a subset of lung tumors. With clin-
ical trials underway to evaluate the efficacy of CB-839 against
these cancers, it will be important to characterize further the
function of GLS2 in these contexts. In pancreatic ductal adeno-
carcinoma (PDAC) cells, GLS inhibitors have only a temporary
cytostatic effect, which is followed by metabolic adaptation and
recovery of proliferation (Biancur et al., 2017). Notably, GLS2 is
present in both healthy pancreas and PDAC cells (Altman et al.,
2016; Biancur et al., 2017), and thusmight provide a critical supply
of glutamate following GLS inhibition. The sensitivity of some can-
cer cells toGLS inhibitors requires high expressionof the xCT anti-
porter, which exchanges intracellular glutamate for extracellular
cystine and can therefore deplete intracellular glutamate reserves
(Muir et al., 2017). Thus, a signature of concurrent high expression
of GLS and xCT, along with low levels of GLS2, might identify
tumors that are most likely to respond to GLS-targeted therapy.
GLS2 as a Potential Therapeutic Target
In healthy tissues, GLS2 expression is highest in periportal re-
gions of the liver, where it allows glutamine carbon to be directed
via the TCA cycle into the gluconeogenic pathway in response to
glucagon (Lacey et al., 1981; Watford and Smith, 1990). For
GLS2 to be targeted for cancer therapy, any toxicity arising
from inhibiting its normal physiological function must be within
a tolerable range. We observed that mice treated with 968 at
10 mg/kg body weight, three times weekly for 3 weeks, showed
no gross evidence of toxicity. Moreover, it was recently reported
thatGLS2 knockout mice are viable, albeit with a decreased abil-
ity to maintain plasma glucose levels during fasting (Miller et al.,
2018). These results indicate that GLS2 could be safely targeted
as a strategy for treating luminal-subtype breast cancers, most
likely as part of a combination therapy designed to maximize
cancer cell dependence on the glutaminase reaction. To date,
drug discovery efforts for blocking glutamine catabolism in can-
cer have focused almost exclusively on the GLS isozyme. How-
ever, a small number of molecular scaffolds have now been re-
ported to inhibit GLS2 (Wu et al., 2018), including 968, which
we show targets both isozymes with a moderate (3-fold) selec-
tivity for GLS2. Our finding that GLS2 is upregulated and essen-
tial in the most prevalent subtypes of breast cancer support the
notion of building on these scaffolds to develop more potent
inhibitors for selective targeting of GLS2-high cancers.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Cell Lines
Human breast cancer cell lines MCF7, BT-474, T-47D, MDA-MB-453, MDA-MB-231, Hs 578T, HCC38, SK-BR-3, and DU4475 were
purchased from the American Type Culture Collection (ATCC) and no additional cell authentication was performed. The TSE human
breast cancer cell line was supplied by Dr. Steven Abcouwer (University of Michigan). All breast cancer cells were cultured at 37C
under a 5% CO2 atmosphere in RPMI 1640 medium containing 2 mM glutamine (GIBCO) and supplemented with 10% fetal bovine
serum (FBS) (GIBCO). The 293T cell line (ATCC) used for generating lentivirus particles was cultured as above but using DMEM, high
glucose (GIBCO).
Animals
All experiments involving mice were carried out according to protocols approved by the Institutional Animal Care and Use
Committee at Cornell University. In all cases, 6-8 week old female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (The Jackson Lab-
oratory) were used. For xenograft experiments, a suspension of MDA-MB-453 breast cancer cells (or derivative cell lines stably
expressing shRNAs) was mixed 1:1 with Matrigel Matrix (BD Biosciences) to give a final concentration of 3 3 106 cells per
100 ml, and 3 3 106 cells were immediately injected into each of the two flanks of 6-8 week old female NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ (NSG) mice (n = 3 mice per condition). Tumor sizes were measured using calipers, and estimated volumes were
calculated using the formula V = (p/6)3 length3width2, as described previously (Tomayko and Reynolds, 1989). For experiments
using MDA-MB-453 cells stably expressing shRNAs, mice were sacrificed after 6 weeks. For 968 treatment studies, when tumors
of 1-2 mm diameter were detected, the mice were randomly divided into two groups and intraperitoneal (IP) injections of 968
(10mg/kg) solution or carrier solution were initiated and carried out three times weekly. The formulation was prepared immediately
prior to injection and consisted of 70% PBS, 20% Cremophor EL, 10% DMSO, and 968 diluted from a 21 mM DMSO stock. Mice
were sacrificed after 3 weeks of treatment.Cell Reports 29, 76–88.e1–e7, October 1, 2019 e3
METHOD DETAILS
Cell Lysis and Western Blot Analysis
Cells, or fractionatedmitochondria and nuclei, were lysedwith ice-cold lysis buffer (50mMHEPESpH8.0, 150mMNaCl, 25mMNaF,
1% (v/v) Triton X-100, 1 mMMgCl2, 50 mM b-glycerophosphate, 30 mg/ml leupeptin, 5 mg/ml aprotinin), and insoluble debris cleared
by centrifugation at 4C. Protein concentrations were determined by Bradford assay (Bio-Rad), and lysate was then boiled for 10 min
in reducing SDS-sample buffer. Lysate proteins (20 mg total protein/lane, except for the cell fractionation experiment in which 5 mg
total protein/lane was used) were then resolved on Novex 12% Tris-Glycine Mini Gels (Thermo Fisher Scientific) and transferred to
PVDFmembrane (PerkinElmer). Membranes were blocked in 7%BSA in Tris-Buffered Saline plus 0.05% TWEEN 20 (TBST) for 1 h at
room temperature and probed overnight at 4C in primary antibody solution in TBST (see Table S5 for antibody dilutions). They were
then washed with TBST and incubated in TBST containing 25% (v/v) non-fat dry milk powder and anti-Rabbit or anti-Mouse second-
ary antibody (1:2500) for 1 h. Finally, membranes were washed in TBST, and imaged usingWestern Lightning Plus-ECL (PerkinElmer)
and HyBlot ES autoradiography film (Denville Scientific Inc.).
Breast Tumor Tissue Microarray
Tissue microarray BRC961 (US Biomax) was probed as follows, using the anti-GLS2 antibody (Abgent, AP6650D). Reagents were
from Vector Laboratories VECTASTAIN Elite ABC HRP kit (Cat# PK-6200), Avidin/Biotin blocking kit (Cat# SP-2001), and ImmPACT
DAB Peroxidase (HRP) Substrate (Cat# SK-4105). Deparaffinization was carried out by heating the slide to 60C for 20 min and then
immersing the slide in mixed xylenes (23 10 min), 100% ethanol, 95% ethanol, 70% ethanol (5 min each) and finally H2O (23 5 min).
The antigen retrieval step involved immersing the slide in 10mM sodium citrate buffer, pH 6.0 at95C for 15min and then cooling at
room temperature for 20 min. To remove endogenous peroxidase the slide was washed with H2O (23 5 min) and then incubated in
3% H2O2 in H2O for 10 min. The slide was then washed in H2O for 5 min followed by PBS for 5 min. Blocking was carried out at room
temperature using horse serum (20min), PBS rinse, avidin solution (15min), PBS rinse, biotin solution (15min), PBS rinse, followed by
PBS washes (23 5 min). The slide was then incubated overnight at 4C with the anti-GLS2 primary antibody (1:100 in horse serum).
Next, the slide was washed with PBS (4 3 5 min), incubated for 30 min at room temperature with biotinylated universal secondary
antibody, and washed again with PBS (43 5 min). Then, the slide was incubated for 30 min at room temperature with VECTASTAIN
ABC reagent andwashed again with PBS (43 5min). To develop, the slide was incubated with diluted ImmPACTDAB chromogen for
2 min and then washed in H2O (2 3 5 min). Finally, the stained slide was dehydrated by immersing in 70% ethanol, 95% ethanol,
100% ethanol (5 min each) and mixed xylenes (2 3 5 min), mounted using Permount mounting medium (Fisher) and sealed. Signal
intensity was quantified using ImageJ. Receptor staining intensity data were from US Biomax.
RNA Isolation and Quantitative Real-Time PCR
Total RNAwas extracted from cells using the RNeasyMini Kit (QIAGEN) andQIAshredder (QIAGEN), and cDNAswere prepared using
SuperScript III Reverse Transcriptase (Thermo Fisher Scientific). RT-PCR was carried out using the 7500 fast real-time PCR system
(Applied Biosystems), using appropriate primers (Table S6) with cDNA as the template. In all cases, 18S rRNA served as the endog-
enous control. All primer sequences were obtained from PrimerBank (https://pga.mgh.harvard.edu/primerbank/), and primers were
synthesized by Integrated DNA Technologies. Reactions were carried out using Power SYBR Green PCR Mix (Thermo Fisher
Scientific).
Genomic DNA Isolation and DNA Methylation Analysis
Highmolecular weight genomic DNAwas isolated from breast cancer cells using QIAamp DNAMini Kit (QIAGEN), and contaminating
RNA was digested using RNase One Ribonuclease (Promega) followed by re-purification of DNA, elution with water, and adjustment
of DNA concentration to 50 ng/ml. To assess DNA purity, UV/visible absorption spectra weremeasured, and for all samples the A260/
280 ratio was >1.7 and the A260/230 ratio was >2.0. Samples were then submitted to the Epigenomics Core at Weill Cornell Medical
College, where bisulfite conversion was carried out followed by DNA methylation analysis using Mass ARRAY EpiTYPER1.2 Suite
(Agena Bioscience). The sequence of the CpG island in the GLS2 gene promoter was obtained from human reference genome
GRCh38/hg38 using the UCSC Genome Browser (https://genome.ucsc.edu). Primers for DNA methylation analysis were designed
using EpiDesigner (Agena Bioscience) and synthesized by Integrated DNA Technologies (Table S6). Relative methylation ratios at
CpG sites are presented as a heatmap, generated using MORPHEUS (https://software.broadinstitute.org/morpheus).
Immunofluorescence
Cells were fixed with 3.7% formaldehyde in PBS for 20 min and then permeabilized with PBS containing 0.1% Triton X-100 (v/v) for
20 min. Samples were blocked with 10% BSA (w/v) in PBS for 1 h, rinsed with PBS and then incubated with primary antibody in PBS
containing 5% BSA (w/v) for 2 h. Samples were washed 3 times with PBS, and then Texas Red- or Oregon Green 488-conjugated
secondary antibody diluted 1:400 in PBS containing 5% BSA (w/v), along with DAPI counterstain, was added for 1 h. Samples were
washed 3 times with PBS, mounting medium was applied, and slides were sealed with a coverslip prior to imaging with a ZEISS
Axioscope.e4 Cell Reports 29, 76–88.e1–e7, October 1, 2019
Cell Fractionation and Mitochondrial Isolation
Breast cancer cells were fractionated into cytosolic, mitochondrial, and nuclear components via partial lysis and centrifugation using
the Qproteome Mitochondria Isolation Kit (QIAGEN). For all samples, a portion of the starting material (i.e., whole cells) was retained
for comparison with the isolated fractions. When cellular fractions were to be analyzed only by western blot, a single 10 cm dish of
exponentially growing cells was used. When mitochondria were isolated for glutaminase assays, two 15 cm dishes of exponentially
growing cells were used.
Mitochondrial Glutaminase Activity Assays
A two-reaction protocol was used to measure mitochondrial glutaminase activity. Mitochondria (5 mg total protein) were added to
105 mL of Reaction Mix 1 (20 mM glutamine, 0.2 mM EDTA, 50 mM Tris-acetate pH 8.6), supplemented with 10 mM BPTES when
appropriate, and samples were incubated at 37C for 40 min. The reaction was then quenched by addition of 10 mL of 2.4 M HCl,
and samples placed on ice. Next, 20 mL of quenched Reaction Mix 1 was added to 200 mL of Reaction Mix 2 (1 unit bovine liver gluta-
mate dehydrogenase (Sigma-Aldrich), 80 mM Tri-HCl pH 9.4, 200mM hydrazine, 0.25 mMADP, 2 mMNAD) and samples were incu-
bated for 1 h at room temperature. The absorbance at 340 nm was then measured against a matched sample in which heat-inacti-
vated mitochondria (immersed in boiling water for 5 min) were used. A standard curve was prepared using given concentrations of
glutamate in Reaction Mix 2, allowing the amount of glutamate produced in Reaction 1 to be determined.
Real-Time Recombinant Glutaminase Activity Assays
Real-timemonitoring of glutaminase activity through NADH production was performed on aCary Eclipse fluorescence spectrometer.
The excitation and emission wavelengths were set at 340 nm and 460 nm, respectively. To a 1mL cuvette, 900 mL of assay buffer was
added, followed by 10 mL of GDH, 40 mL of 50 mM NAD and 20 mL of either DMSO or various dilutions of 968. Then, 100 mL of either
100 nMGAC or 500 nMGLS2was added to this mixture and the fluorescence emission wasmonitored in real time. After 30 s, 200 mL
of a mixture of glutamine and K2HPO4 was added such that the final concentrations of K2HPO4 and glutamine were 100 mM and
20mM, respectively. The initial velocity of glutamine hydrolysis was obtained from the slopes of the linear portion of the kinetic curve.
Glutamine Consumption and Glutamate Release Assays
To 6-well plates containing 2mL phenol red-free culturemedium/well, 23 105 cells/well were added and incubated overnight to atta-
ch. Wells were then rinsed twice with serum-free, phenol red-free culture medium, and 2 ml/well fresh serum-free/phenol red-free
medium (containing 2 mM glutamine) was added, followed by incubation for 19 h. As a negative control, wells containing culture me-
dium only were used. Mediumwas then collected, cellular debris removed by centrifugation at 4C, and the supernatant retained and
stored on ice. Meanwhile, cells attached to the wells were lysed and total protein was quantified using the Bradford assay. Glutamine
concentrations were determined using the L-Glutamine/Ammonia Assay Kit (Rapid) (Megazyme) following the manufacturer’s in-
structions. Briefly, 50 mL sample was mixed with 100 mL Assay Buffer 1 and 10 mL Glutaminase Suspension and incubated at
room temperature for 5 min. For all reactions, a blank containing 50 mL H2O was run in parallel. Then, 150 mL Assay Buffer 2,
100 mL NADPH Solution, and H2O to bring the final volume to 1160 mL was added, followed by incubation at room temperature
for 4 min. Absorbance A1 was then measured at 340 nm. Next, 10 mL Glutamate Dehydrogenase Suspension was added, samples
were mixed and incubated at room temperature for 5 min, and absorbance A2 was measured at 340 nm. Sample concentrations of
glutamine were calculated using the extinction coefficient of NADPH at 340 nm. Changes in sample glutamine concentrations were
measured relative to the culture medium samples which had been incubated in cell-free wells. Tomeasure glutamate levels in culture
medium, samples were analyzed by Reaction 2 described above for the mitochondrial glutaminase activity assays.
Cell Proliferation Assays
Culture medium was added to 12-well plates (1 ml/well) and wells were seeded with cells at Day 0 as follows. MCF7, T-47D, BT-474,
HCC38 cells: 23 104 cells/well. MDA-MB-453 andMDA-MB-231 cells: 13 104 cells/well. TSE andHs 578T cells: 0.33 104 cells/well.
After 16 h, culture medium was replaced with fresh medium supplemented with appropriate concentrations of inhibitors and was
subsequently replaced every 48 h. On Day 6 cells were trypsinized and suspended in an appropriate volume of culture medium,
and the total number of cells per well was determined using a hemocytometer or a TC20 Automated Cell Counter (Bio-Rad).
DNA Constructs for Expressing GLS and GLS2
Vectors for expressing human GAC or GLS2 in breast cancer cell lines were based on pCDNA3.1/V5-His TOPO (Thermo Fisher Sci-
entific), with the appropriate gene sub-cloned in and the tag switched to HA-tag or myc-tag for immunofluorescence experiments.
Vectors pQE80-GAC-72-598 and pQE80-GLS2-38-602, for expressing the processed forms of human GAC (residues 72 to 598) or
GLS2 (residues 38 to 602) in E. coli, were described in Huang et al. (2018).
Expression and Purification of Recombinant GAC and GLS2
Recombinant GAC and GLS2 were expressed in E. coli as described in Huang et al. (2018). Briefly, E. coli strain BL21(DE3) (Thermo
Fisher Scientific) were transformed with vector pQE80-GAC-72-598 or with pQE80-GLS2-38-602 to express the processed forms of
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harvested by centrifugation and lysed by sonication in binding buffer (500mMNaCl, 50 mM Tris-HCl pH 8.5, 10 mM imidazole, 5 mM
b-mercaptoethanol, 1mMbenzamidine chloride). The lysate was centrifuged, and the supernatant applied to a Ni-NTA columnwhich
was then washed with 100 column volumes of binding buffer followed by 10 volumes of wash buffer (500 mM NaCl, 50 mM Tris-HCl
pH 8.5, 40 mM imidazole, 5 mM b-mercaptoethanol, 1 mM benzamidine chloride). Protein was eluted with 5 column volumes of
elution buffer (500 mM NaCl, 300 mM imidazole-HCl pH 7.5, 5 mM b-mercaptoethanol, 1 mM benzamidine chloride). The eluate
was centrifugally concentrated and then further purified by FPLC using a HiLoad 16/600 Superdex 200 column (GE Healthcare)
with 150 mM NaCl, 5 mM Tris-HCl pH 7.5.
Transfection of Breast Cancer Cells with DNA Constructs
For 60 mm dish format. 0.2 mL Opti-MEM (GIBCO) containing 1.5 mg of the appropriate DNA construct, along with 0.2 mL Opti-MEM
containing 12 mL Lipofectamine 2000 (Invitrogen), were separately incubated at room temperature for 5 min. The two solutions were
combined and incubated for an additional 20 min, mixed with 1.6 mL culture medium and added to cells. After 5 h incubation at 37C
the transfection mixture was replaced with fresh culture medium, and cells were then incubated for an additional 48 h to allow for
ectopic expression of GLS or GLS2. To select for cells stably expressing the DNA construct, culture medium supplemented with
500 mg/ml G-418 disulfate (Research Products International) was added and replaced every 2 days for 2-3 weeks until isolated col-
onies2 mm in diameter were present. Individual colonies were transferred to a 12-well plate (1 colony per well) using sterile blotting
paper soaked in trypsin solution and were then cultured in medium supplemented with 250 mg/ml G-418 disulfate. All colonies were
screened by western blot for ectopic expression, and positive clones were maintained in medium supplemented with 250 mg/ml
G-418 disulfate.
Genetic Knockdowns using siRNAs
Transient knockdowns of GATA3, GLS, and GLS2 were achieved using two rounds of transfection with Silencer Select pre-designed
siRNAs (Invitrogen). For 60 mm dish format, 0.3 mL Opti-MEM (GIBCO) containing 100 nM of the appropriate siRNA (to give a final
siRNA concentration of 10 nMwhen diluted as below), alongwith 0.3mLOpti-MEMcontaining 12 mL Lipofectamine 2000 (Invitrogen),
were incubated separately at room temperature for 5 min. The two solutions were then combined and incubated for an additional
20 min, mixed with 2.4 mL culture medium, and added to cells. After 5 h incubation at 37C the transfection mixture was replaced
with fresh culture medium. For all knockdowns, two independent siRNAs were used, along with a negative control siRNA.
Genetic Knockdowns using shRNAs
The MISSION RNAi system (Sigma-Aldrich) was used for shRNA-mediated knockdown of GLS and GLS2. Lentivirus particles for
each shRNA construct were generated using exponentially growing 293T cells (ATCC) as follows. For 10 cm dish format, 570 mL
DMEM was mixed with 33 mL FuGENE 6 (Promega) and incubated at room temperature for 5 min. Plasmids pLKO.1-shRNA
(5 mg), pCMV-dR8.2 (packaging vector) (5 mg), and pMD2.G (envelope vector) (1 mg) were then added to the solution, incubated
for an additional 15 min, mixed with 8 mL culture medium and added to cells. Cells were incubated at 37C overnight and the trans-
fection medium was then replaced with fresh culture medium, followed by an additional 24 h incubation to allow for production of
virus particles. Virus-containing mediumwas then collected, and cellular debris removed by centrifugation. To transduce breast can-
cer cells, virus-containing supernatant was diluted 1:12 in fresh culturemedium, and 6 mg/ml polybrene was added before applying to
cells. After 6 h incubation at 37C the transduction medium was replaced with fresh culture medium, and cells were incubated for an
additional 48 h before knockdowns were validated. For both GLS and GLS2 knockdowns, two independent shRNA constructs were
used, and for all experiments the effects of knockdownwere compared with those of a control shRNA. To select for stable expression
of the constructs, cells were cultured in medium containing 0.5 mg/ml puromycin.
Data from The Cancer Genome Atlas
Gene expression data (RNA-Seq V2, RSEM) from TCGA invasive breast cancer dataset (Koboldt et al., 2012) were accessed using
UCSC Xena (https://xena.ucsc.edu) or cBioPortal (http://www.cbioportal.org). Breast tumor subtype calls made by UCSC Xena
were based on RNA-Seq data. Outlier readings are not shown on box and whisker plots but are included in calculation of the
mean. Copy-number analysis data were accessed using cBioPortal.
Metabolite Extraction
The procedures for metabolite extraction from cultured cells are described in previous studies (Cluntun et al., 2015; Liu et al., 2014).
Briefly, adherent cells were grown in 6-well plates in biological triplicate to 80% confluence, medium was rapidly aspirated and cells
were washed with cold PBS on ice. Then, 1 mL of extraction solvent (80%methanol/water) cooled to80Cwas added to each well,
and the dishes were transferred to 80C for 15 min. Cells were then scraped into the extraction solvent on dry ice. All metabolite
extracts were centrifuged at 20,0003 g at 4C for 10min. Finally, the solvent in each sample was evaporated in a Speed Vacuum. The
cell extracts were dissolved in 15 mL water and 15 mL methanol/acetonitrile (1:1 v/v) (LC-MS optima grade, Thermo Fisher Scientific).
Sampleswere centrifuged at 20,0003 g for 10min at 4Cand the supernatants were transferred to Liquid Chromatography (LC) vials.
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For metabolite abundances in Figure S4 a slightly modified protocol was used, as follows. The cell extracts were dissolved in 50 mL
water (LC-MS optima grade, Thermo Fisher Scientific) and sonicated to ensure analytes were completely dissolved. Samples were
centrifuged at 18,0003 g for 30 min at 4C and the supernatants were transferred to Liquid Chromatography (LC) vials. The injection
volume for polar metabolite analysis was 1 ml.
[U-13]-Glutamine Labeling
Cells were grown to 80% confluence in 6-well plates with standard culture medium and washed with sterile PBS. Then, culture
medium in which glutamine was replaced by [13C5]-L-glutamine (Cambridge Isotope Laboratories), supplemented with dialyzed
FBS (GIBCO) and appropriate concentrations of inhibitors was added (1.5 ml/well). At the appropriate time-point, metabolites
were extracted as described above.
Liquid Chromatography
A hydrophilic interaction liquid chromatography method (HILIC) with an Xbridge amide column (1003 2.1 mm, 3.5 mm) (Waters) was
employed on a Dionex (Ultimate 3000UHPLC) for compound separation and detection at room temperature. Themobile phase Awas
20 mM ammonium acetate and 15 mM ammonium hydroxide in water with 3% acetonitrile, pH 9.0, and the mobile phase B was
acetonitrile. The linear gradient was as follows: 0 min, 85% B; 1.5 min, 85% B, 5.5 min, 35% B; 10 min, 35% B, 10.5 min, 35% B,
14.5 min, 35% B, 15 min, 85% B, and 20 min, 85% B. The flow rate was 0.15 ml/min from 0 to 10 min and 15 to 20 min, and
0.3 ml/min from 10.5 to 14.5 min. All solvents were LCMS grade and purchased from Thermo Fisher Scientific.
For metabolite abundances in Figure S4 a slightly modified protocol was used, as follows. A hydrophilic interaction liquid chroma-
tography method (HILIC) with an ZORBAX HILIC Plus column (1503 2.1 mm, 1.8 mm) (Agilent) was employed on a Dionex (Ultimate
3000 UHPLC) for compound separation and detection at room temperature. The mobile phase Water with 0.1% formic acid was
mobile phase A and acetonitrile with 0.1% formic acid was mobile phase B. The linear gradient was as follows: 0 min, 95% B;
1.5 min, 95% B, 15.5 min, 50% B; 16.5 min, 10% B, 18.5 min, 10% B, 18.6 min, 95% B, 21 min, 95% B, and total flow rate was
0.5 ml/min. All solvents were LCMS grade and purchased from Thermo Fisher Scientific.
Mass Spectrometry
The Q Exactive MS (Thermo Scientific) is equipped with a heated electrospray ionization probe (HESI), and the relevant parameters
are as listed: evaporation temperature, 120C; sheath gas, 30; auxiliary gas, 10; sweep gas, 3; spray voltage, 3.6 kV for positive mode
and 2.5 kV for negative mode. Capillary temperature was set at 320C, and S-lens was 55. A full scan range from 60 to 900 (m/z) was
used. The resolution was set at 70,000. The maximum injection time was 200 ms. Automated gain control (AGC) was targeted at
3,000,000 ions.
For metabolite abundances in Figure S4 a slightly modified protocol was used, as follows. The Q Exactive HF (Thermo Scientific) is
equipped with a heated electrospray ionization probe (HESI), and the relevant parameters are as listed: evaporation temperature,
120C; sheath gas, 60; auxiliary gas, 20; sweep gas, 1; spray voltage, 3.0 kV for negative mode. Capillary temperature was set at
380C, and S-lens was 50. A full scan range from 80 to 300 (m/z) was used. The resolution was set at 240,000. Themaximum injection
time was 500 ms. Automated gain control (AGC) was targeted at 3,000,000 ions.
Metabolomics and Data Analysis
Raw data collected from LC-Q Exactive MSwere processed on Sieve 2.0 (Thermo Scientific) and ToxID 2.0 (Thermo Scientific). Peak
alignment and detection were performed according to the protocol described by Thermo Scientific. For targetedmetabolite analysis,
the method ‘peak alignment and frame extraction’ was applied. An input file of theoretical m/z and detected retention time of 204
known metabolites was used for targeted metabolites analysis with data collected in positive mode, while a separate input file of
278 metabolites was used for negative mode. M/Z width was set at 10 ppm. The output file including detected m/z and relative in-
tensity in different samples was obtained after data processing. The quantity of the metabolite fraction analyzed was adjusted to the
corresponding protein concentration and cell count upon processing a parallel 6-well plate. Quantitation and statistics were calcu-
lated and visualized with Microsoft Excel, MORPHEUS and MetaboAnalyst online software.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data are shown as mean ± standard deviation (SD) or mean ± standard error of the mean (SEM), and the number of replicates is indi-
cated in the figure legends. Statistical significance was determined using a two-tailed Student’s t-test. Significance: *p% 0.05, **p%
0.01.
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